Intra-cellular Therapies, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Intra-Cellular Therapies' stockholders have approved the merger agreement with Johnson & Johnson, paving the way for the company to become a wholly-owned subsidiary.
Intra-Cellular Therapies supplements its proxy statement related to the proposed merger with Johnson & Johnson, addressing stockholder lawsuits alleging disclosure deficiencies.
8-K: Intra-Cellular Therapies Merger with Johnson & Johnson Advances as HSR Act Waiting Period Expires
Intra-Cellular Therapies' merger with Johnson & Johnson progresses as the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expires.
Intra-Cellular Therapies announces a 47% increase in CAPLYTA net product sales for 2024, reaching $680.5 million, and the FDA's acceptance of its sNDA for adjunctive treatment of major depressive disorder (MDD).
Johnson & Johnson will acquire Intra-Cellular Therapies for $132 per share in cash, totaling approximately $14.6 billion, to expand its neuroscience offerings.
Intra-Cellular Therapies has reached a settlement with Sandoz, allowing Sandoz to sell generic versions of CAPLYTA starting July 1, 2040, or earlier under certain conditions.
Intra-Cellular Therapies has submitted a supplemental New Drug Application to the FDA for CAPLYTA as an adjunctive therapy for major depressive disorder.
Intra-Cellular Therapies reports positive topline results from a Phase 3 trial showing CAPLYTA significantly reduces the risk of relapse in schizophrenia patients compared to placebo.
Intra-Cellular Therapies announced a 39% increase in CAPLYTA net product sales for Q3 2024 compared to the same period last year, and raised its full-year sales guidance.
Intra-Cellular Therapies announced the appointment of Sanjeev Narula as CFO, alongside strong Q2 financial results and an increased sales guidance for CAPLYTA.
Intra-Cellular Therapies' stockholders approved an amendment to their 2018 Equity Incentive Plan, increasing share reserves and extending the plan's termination date.
Intra-Cellular Therapies reports successful topline results from a Phase 3 trial of lumateperone as an adjunctive treatment for major depressive disorder, paving the way for a supplemental New Drug Application.
Intra-Cellular Therapies announced a 53% increase in CAPLYTA net product sales for Q1 2024, alongside positive Phase 3 trial results for adjunctive MDD treatment.
Intra-Cellular Therapies successfully closed a public offering, raising approximately $575 million through the sale of common stock, including the full exercise of the underwriters' option.
Intra-Cellular Therapies has priced a public offering of 6,849,316 shares of common stock at $73.00 per share, expecting gross proceeds of $500 million.
8-K: Intra-Cellular Therapies Announces $500 Million Public Offering and Preliminary Q1 2024 Results
Intra-Cellular Therapies has announced a $500 million public offering of common stock and provided preliminary first quarter 2024 results, including $144.8 million in CAPLYTA net product sales.
Intra-Cellular Therapies' lumateperone 42 mg demonstrated statistically significant and clinically meaningful improvements in major depressive disorder symptoms when used as an adjunctive therapy to antidepressants in a Phase 3 trial.
Intra-Cellular Therapies has initiated patent infringement lawsuits against seven generic drug manufacturers seeking to market generic versions of its drug, CAPLYTA.
Intra-Cellular Therapies has promoted Michael Halstead to President and announced the retirement of CFO Lawrence Hineline after 20 years of service.
Intra-Cellular Therapies announced a significant increase in revenue for 2023, driven by strong sales of CAPLYTA, and provided updates on its clinical pipeline.